February 25, 2016 | By Tracy Staton in FiercePharma
In an article in Science Translational Medicine, researchers from the Massachusetts Institute of Technology, Dana-Farber Cancer Institute and the Broad Institute say patient loans could be designed to link payment to the clinical benefits of their treatment. In a way, they would be pay-for-performance deals–an idea now taking hold with Big Pharma in negotiations with payers–but at the patient level.
According to the researchers, coupling loan payments to treatment results could not only lower per-patient costs–by making sure that only patients who get results have to pay–but also offer an incentive for drugmakers to focus on “transformative therapies rather than those that offer small incremental advances,” such as “me-too” meds or slightly-tweaked follow-ups to aging blockbusters.
Read the full story in: http://www.fiercepharma.com/story/Dana-Farber-MIT-researchers-tout-performance-linked-securitized-loans-drug-financing/2016-02-25
or here: http://stm.sciencemag.org/content/8/327/327ps6.full